M&A / Deals

• M&A / Deals

Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data

pharminent April 8, 2026

• M&A / Deals

RoosterBio and MineBio team up to expand MSC solutions access in China

pharminent April 8, 2026

• M&A / Deals

Halozyme and Vertex sign deal for Hypercon technology

pharminent April 8, 2026

• M&A / Deals

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

pharminent April 7, 2026

• M&A / Deals

Gilead outlays $5bn to acquire ADC specialist Tubulis

pharminent April 7, 2026

• M&A / Deals

Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis

pharminent April 7, 2026

• M&A / Deals

Gilead strikes again, penning $5bn deal to buy Tubulis

pharminent April 7, 2026

• M&A / Deals

AI giant Anthropic buys Coefficient Bio for $400m

pharminent April 7, 2026

• M&A / Deals

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

pharminent April 6, 2026

• M&A / Deals

Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

pharminent April 6, 2026

• M&A / Deals

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

pharminent April 3, 2026

• M&A / Deals

Merck KGaA acquires JSR chromatography business

pharminent April 2, 2026

• M&A / Deals

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

pharminent April 2, 2026

• M&A / Deals

Merck KGaA acquires JSR chromatography business

pharminent April 2, 2026

• M&A / Deals

Alzheimer’s biotech Korsana to go public via reverse merger

pharminent April 2, 2026

• M&A / Deals

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

pharminent April 1, 2026

• M&A / Deals

Ambrosia adds a megaround for obesity drugs

pharminent April 1, 2026

• M&A / Deals

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

pharminent April 1, 2026

• M&A / Deals

Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B

pharminent April 1, 2026

• M&A / Deals

Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout

pharminent April 1, 2026

• M&A / Deals

Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa

pharminent April 1, 2026

• M&A / Deals

Symeres and Ambagon collaborate for colorectal cancer molecules

pharminent April 1, 2026

• M&A / Deals

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

pharminent March 31, 2026

• M&A / Deals

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

pharminent March 31, 2026

• M&A / Deals

Biogen, with $5.6B Apellis buy, builds out immunology offerings

pharminent March 31, 2026

• M&A / Deals

Biogen swoops on Apellis with $5.6bn offer

pharminent March 31, 2026

• M&A / Deals

Eli Lilly makes $7.8bn takeover play for Centessa

pharminent March 31, 2026

• M&A / Deals

Merck strikes deal with antibody discovery startup

pharminent March 31, 2026

• M&A / Deals

Blackstone closes $6.3B fund for life sciences investing

pharminent March 30, 2026

• M&A / Deals

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

pharminent March 29, 2026

• M&A / Deals

Lilly puts up to $2.75bn into Insilico alliance

pharminent March 29, 2026

• M&A / Deals

Otsuka picks up PTSD drug with $700M Transcend buy

pharminent March 27, 2026

• M&A / Deals

Novartis targets Xolair successor in buyout of startup Excellergy

pharminent March 27, 2026

• M&A / Deals

Merck’s deal for Terns sparks debate over a possible biotech bidding war

pharminent March 26, 2026

• M&A / Deals

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

pharminent March 25, 2026

• M&A / Deals

Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

pharminent March 24, 2026

• M&A / Deals

RA Capital targets China with latest SPAC deal

pharminent March 24, 2026

• M&A / Deals

Immutrin raises $87M to advance drug for progressive heart disease

pharminent March 24, 2026